stockrow
Friday 6 November 2026
Export OMCL’s income statement to Excel — free account
Omnicell, Inc.
OMCL Healthcare Health Information Services
Omnicell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 6.53% from fiscal 2024.
- Revenue
- −0.89%
- EPS
- +100.0%
- Free cash flow
- +42.6%
- Total debt
- +0.73%
Quarter to September 2026, against a year earlier
37.33
0.70
−1.84%
Follow OMCL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
35.10 | 48.85 | 75.86 | 1,132.50 |
+8 more quarters Free account |
P/S ratio |
1.26 | 1.52 | 1.23 | 1.76 | |
P/FCF ratio |
11.77 | 14.94 | 15.47 | 30.02 | |
P/Operating CF |
47.28 | 27.72 | 27.76 | 68.60 | |
P/B ratio |
1.19 | 1.47 | 1.20 | 1.69 | |
Price to Tangible BV |
3.69 | 4.81 | 4.27 | 6.43 | |
EV/Sales |
1.28 | 1.56 | 1.32 | 1.88 | |
EV/EBITDA |
10.61 | 13.45 | 13.32 | 23.59 | |
EV/Operating CF |
8.54 | 10.72 | 10.37 | 17.50 | |
EV/FCF |
11.99 | 15.34 | 16.52 | 32.12 | |
Quick Ratio |
1.16 | 1.16 | 1.01 | 0.87 | |
Current Ratio |
1.66 | 1.64 | 1.50 | 1.43 | |
Net Debt/EBITDA |
(4.09) | (2.31) | (1.88) | (1.27) | |
Debt/Assets |
8.19% | 8.41% | 8.38% | 8.49% | |
Debt/Equity |
0.13 | 0.13 | 0.13 | 0.14 | |
Asset Turnover |
0.62 | 0.60 | 0.59 | 0.58 | |
Operating CF/Net income |
2.99 | 2.81 | 4.80 | (14.98) | |
Capex/Depreciation |
(0.63) | (0.59) | (0.76) | (0.54) | |
Interest Coverage |
— | (23.45) | — | — | |
Research and Development Expense of Revenue |
7.26% | 6.50% | 6.94% | 7.18% | |
Selling, General and Administrative Expense of Revenue |
32.66% | 32.09% | 32.91% | 34.19% | |
Intangible Assets out of Total Assets |
0.43 | 0.45 | 0.45 | 0.46 | |
Share Based Compensation of Revenue |
3.71% | 3.91% | 3.07% | 3.81% | |
Graham Net Nets |
0.03 | 0.01 | (0.02) | (0.03) | |
Graham Number |
25.03 | 23.27 | 16.57 | 4.91 | |
Earnings Yield |
2.85% | 2.05% | 1.32% | 0.09% | |
Free Cash Flow Yield |
8.49% | 6.69% | 6.47% | 3.33% | |
Revenue per Share |
6.71 | 6.85 | 6.84 | 6.83 | |
Operating CF per Share |
0.72 | 1.50 | 1.20 | 0.66 | |
Capex per Share |
(0.29) | (0.27) | (0.35) | (0.26) | |
Free Cash Flow per Share |
0.43 | 1.22 | 0.85 | 0.40 | |
Cash per Share |
6.86 | 6.41 | 5.28 | 4.28 | |
Shareholders Equity per Share |
28.70 | 28.32 | 27.73 | 26.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.70 | 28.32 | 27.73 | 26.80 | |
Free Cash Flow |
19.95 | 55.78 | 38.63 | 18.36 | |
Working Capital |
310.28 | 287.95 | 239.25 | 203.46 | |
Capital Expenditures |
(13.10) | (12.53) | (15.87) | (11.99) | |
Net Current Asset Value |
44.40 | 28.13 | (25.17) | (62.84) | |
EV/EBIT |
24.61 | 33.55 | 48.06 | 431.81 | |
Capex to Sales |
0.04 | 0.04 | 0.05 | 0.04 | |
Price to Operating Income |
24.17 | 32.67 | 44.98 | 403.54 | |
| Other line items | |||||
Average Receivables |
240.88 | 229.87 | 250.70 | 236.63 | |
Average Payables |
61.66 | 56.10 | 55.81 | 47.89 | |
Average Inventory |
102.85 | 101.25 | 95.17 | 94.78 | |
Average Assets |
2,002.72 | 2,072.18 | 2,077.79 | 2,047.84 | |
Average Common Equity |
1,269.08 | 1,277.61 | 1,256.87 | 1,237.56 |
Columns are period end dates · fundamentals updated 6 Nov 2026